EcoDrugPlus

Histone Deacetylase 7

Ensembl ID : ENSCAFG00020011273
Gene Symbol: HDAC7
3 Cross references
263 Possible Orthologues:

Histone Deacetylase 8

Ensembl ID : ENSCAFG00020021326
Gene Symbol: HDAC8
3 Cross references
204 Possible Orthologues:

Histone Deacetylase 9

Ensembl ID : ENSCAFG00020001908
Gene Symbol: HDAC9
3 Cross references
233 Possible Orthologues:

Hydroxycarboxylic Acid Receptor 2

Ensembl ID : ENSCAFG00020016345
Gene Symbol: LOC112676487
2 Cross references
164 Possible Orthologues:

Hydroxysteroid 11-Beta Dehydrogenase 1

Ensembl ID : ENSCAFG00020013207
Gene Symbol: HSD11B1
3 Cross references
267 Possible Orthologues:

Hyperpolarization Activated Cyclic Nucleotide Gated Potassium Channel 4

Ensembl ID : ENSCAFG00020004326
Gene Symbol: HCN4
3 Cross references
288 Possible Orthologues:

Hypocretin Receptor 1

Ensembl ID : ENSCAFG00020024868
Gene Symbol: HCRTR1
3 Cross references
95 Possible Orthologues:

Hypocretin Receptor 2

Ensembl ID : ENSCAFG00020013415
Gene Symbol: HCRTR2
3 Cross references
199 Possible Orthologues:

Indoleamine 2,3-Dioxygenase 1

Ensembl ID : ENSCAFG00020002699
Gene Symbol: IDO1
3 Cross references
98 Possible Orthologues:

Inhibitor Of Nuclear Factor Kappa B Kinase Subunit Beta

Ensembl ID : ENSCAFG00020003481
Gene Symbol: IKBKB
3 Cross references
197 Possible Orthologues:

Inosine Monophosphate Dehydrogenase 1

Ensembl ID : ENSCAFG00020021650
Gene Symbol: IMPDH1
3 Cross references
335 Possible Orthologues:

Inosine Monophosphate Dehydrogenase 2

Ensembl ID : ENSCAFG00020020966
Gene Symbol: IMPDH2
3 Cross references
202 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).